| Nov 4 |
IBD 50's No. 2 Stock, Hims & Hers, Smashes Estimates On 'Robust' Obesity Trajectory
|
| Nov 4 |
Hims & Hers Health GAAP EPS of $0.32 beats by $0.27, revenue of $401.6M beats by $18.83M
|
| Nov 4 |
Hims & Hers Health, Inc. Reports Third Quarter 2024 Financial Results
|
| Nov 4 |
Decoding Hims & Hers Health's Options Activity: What's the Big Picture?
|
| Nov 3 |
Hims & Hers Health Q3 2024 Earnings Preview
|
| Oct 30 |
Hims & Hers stock falls 14% after FDA changes semaglutide supply status (update)
|
| Oct 29 |
How Compounded Treatments Are Helping Hims & Hers Customers Meet Their Weight Loss Goals
|
| Oct 27 |
Why compounders and telehealth providers are undeterred by the potential end of the weight-loss drug shortage
|
| Oct 24 |
Ozempic And Wegovy Maker Novo Nordisk Asks FDA To Halt Production Of Compounded Fat Loss Drugs Due To Their 'Inherent Complexity'
|
| Oct 23 |
Him & Hers, WW down on Novo attempt to restrict compounded semaglutide
|
